Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review
TLDR
Improving adherence in schizophrenia may have a considerable positive impact on patients and society by focusing on the identified multitude of factors driving nonadherence, including lack of insight, medication beliefs and substance abuse.Abstract:
Background:Nonadherence to medication is a recognized problem and may be the most challenging aspect of treatment.Methods:We performed a systematic review of factors that influence adherence and the consequences of nonadherence to the patient, healthcare system and society, in patients with schizophrenia. Particular attention was given to the effect of nonadherence on hospitalization rates, as a key driver of increased costs of care. A qualitative systematic literature review was conducted using a broad search strategy using disease and adherence terms. Due to the large number of abstracts identified, article selection was based on studies with larger sample sizes published after 2001. Thirty-seven full papers were included: 15 studies on drivers and 22 on consequences, of which 12 assessed the link between nonadherence and hospitalization.Results:Key drivers of nonadherence included lack of insight, medication beliefs and substance abuse. Key consequences of nonadherence included greater risk of relapse,...read more
Citations
More filters
Journal ArticleDOI
Descriptions and Correlates of Medication Adherence, Attitudes, and Self-Efficacy in Outpatients With Schizophrenia Spectrum Disorders (SSDs).
TL;DR: Level of symptoms was correlated negatively and significantly with self-reported medication adherence and medication adherence self-efficacy, and the effectiveness of a telephone-delivered intervention designed to support adherence was examined.
Journal ArticleDOI
GPs’ views and perspectives on patient non-adherence to treatment in primary care prior to suicide
TL;DR: It is crucial for health professionals to assess patients and manage the possible causes of non-adherence to treatment and policies for increasing treatment adherence, improving services for dual diagnosis, or providing alternative treatments to meet individual patient needs may help to achieve the best health outcomes and could potentially prevent suicide.
Journal ArticleDOI
The impact on health outcome measures of switching to generic medicines consequent to reference pricing: the case of olanzapine in New Zealand.
TL;DR: The study shows that a switch can be made safely from originator olanzapine to a generic brand, and suggests that switching to generics should generally be viewed more positively, and shows that generic reference pricing achieves considerable savings and, as a pricing policy, could be applied more widely.
Journal ArticleDOI
Changing the Drug Delivery System: Does It Add to Non-Compliance Ramifications Control? A Simulation Study on the Pharmacokinetics and Pharmacodynamics of Atypical Antipsychotic Drug.
TL;DR: In this paper, the authors investigated the pharmacokinetic and pharmacodynamic consequences of shifting from Quetiapine fumarate immediate release (IR) to extended-release (XR) formulation in non-adherent schizophrenia patients.
Journal ArticleDOI
Antipsychotic utilization patterns among patients with schizophrenic disorder: a cross-national analysis in four countries
Janet Sultana,Isabel Hurtado,Daniel Bejarano-Quisoboni,Francesco Giorgianni,Krista F. Huybrechts,Zhigang Lu,Elisabetta Patorno,Gabriel Sanfélix-Gimeno,Daniele Ugo Tari,Gianluca Trifirò +9 more
TL;DR: Antipsychotic utilization was heterogeneous among persons with schizophrenic disorder, Nevertheless, low persistence was an issue in all the countries, as less than half of the patients continued their treatment beyond 1 year.
References
More filters
Journal ArticleDOI
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Alessandro Liberati,Douglas G. Altman,Jennifer Tetzlaff,Cynthia D. Mulrow,Peter C Gøtzsche,John P. A. Ioannidis,Mike Clarke,Mike Clarke,Philip J. Devereaux,Jos Kleijnen,David Moher +10 more
TL;DR: An Explanation and Elaboration of the PRISMA Statement is presented and updated guidelines for the reporting of systematic reviews and meta-analyses are presented.
Journal ArticleDOI
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
Alessandro Liberati,Douglas G. Altman,Jennifer Tetzlaff,Cynthia D. Mulrow,Peter C Gøtzsche,John P. A. Ioannidis,Mike Clarke,Mike Clarke,Philip J. Devereaux,Jos Kleijnen,David Moher +10 more
TL;DR: This Explanation and Elaboration document explains the meaning and rationale for each checklist item and includes an example of good reporting and, where possible, references to relevant empirical studies and methodological literature.
Journal ArticleDOI
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Jeffrey A. Lieberman,T. Scott Stroup,Joseph P. McEvoy,Joseph P. McEvoy,Marvin S. Swartz,Robert A. Rosenheck,Diana O. Perkins,Richard S.E. Keefe,Sonia M. Davis,C.E. Davis,Barry D. Lebowitz,Joanne B. Severe,John K. Hsiao +12 more
TL;DR: Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.
Journal ArticleDOI
The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.
Alan S. Bellack,Charles L. Bowden,Christopher R. Bowie,Matthew J. Byerly,William T. Carpenter,Laurel A. Copeland,Albana M Dassori,John M. Davis,Colin A. Depp,Esperanza Diaz,Lisa B. Dixon,John P. Docherty,Eric B. Elbogen,S. Nasser Ghaemi,Paul E. Keck,Samuel J. Keith,Martijn J. Kikkert,John Lauriello,Barry D. Lebotz,Stephen R. Marder,Joseph P. McEvoy,David J. Miklowitz,Alexander L. Miller,Paul A. Nakonezny,Henry A. Nasrallah,Michael W. Otto,Roy H. Perlis,Delbert G. Robinson,Gary S. Sachs,Martha Sajatovic,Nina R. Schooler,S. Charles Schulz,Jan Scoff,Jair C. Soares,Stephen M. Strakowski,Holly A. Swartz,Marcia Valenstein,Dawn I. Velligan,Peter J. Weiden,Emily M. Woltmann,John E. Zeber +40 more
TL;DR: Recommendations for addressing adherence problems to improve patient outcomes are developed, noting that multiple problems may be involved, requiring a combination of interventions.
Journal ArticleDOI
Partial Compliance and Risk of Rehospitalization Among California Medicaid Patients With Schizophrenia
TL;DR: This study showed a direct correlation between estimated partial compliance and hospitalization risk among patients with schizophrenia across a continuum of compliance behavior.
Related Papers (5)
The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.
Alan S. Bellack,Charles L. Bowden,Christopher R. Bowie,Matthew J. Byerly,William T. Carpenter,Laurel A. Copeland,Albana M Dassori,John M. Davis,Colin A. Depp,Esperanza Diaz,Lisa B. Dixon,John P. Docherty,Eric B. Elbogen,S. Nasser Ghaemi,Paul E. Keck,Samuel J. Keith,Martijn J. Kikkert,John Lauriello,Barry D. Lebotz,Stephen R. Marder,Joseph P. McEvoy,David J. Miklowitz,Alexander L. Miller,Paul A. Nakonezny,Henry A. Nasrallah,Michael W. Otto,Roy H. Perlis,Delbert G. Robinson,Gary S. Sachs,Martha Sajatovic,Nina R. Schooler,S. Charles Schulz,Jan Scoff,Jair C. Soares,Stephen M. Strakowski,Holly A. Swartz,Marcia Valenstein,Dawn I. Velligan,Peter J. Weiden,Emily M. Woltmann,John E. Zeber +40 more